Artesunate Exhibits Synergy With Cisplatin and Cytotoxicity for Upper Tract and Bladder Urothelial Carcinoma Cells.
Artesunate
ROS
cisplatin
synergy
urothelial carcinoma
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
30
09
2022
revised:
21
10
2022
accepted:
25
10
2022
entrez:
28
2
2023
pubmed:
1
3
2023
medline:
3
3
2023
Statut:
ppublish
Résumé
Urothelial carcinoma (UC) may arise from the urothelium of the upper tract and the bladder. Cisplatin-based therapy remains the gold standard for UC treatment. The poor 5-year survival rate of UC patients creates an urgent need to develop new drugs for advanced UC therapy. Artesunate (ART), a traditional Chinese medicine for treating malaria, is a potential anticancer agent, but its antigrowth effects on upper tract and bladder UC have not been investigated. The antigrowth effect of ART in HT 1376 (bladder UC cells) and BFTC 909 [upper tract urothelial carcinoma (UTUC) cells] was determined by the CCK-8 assay. Flow cytometric analysis was used to evaluate the cell cycle distribution and apoptosis. The cell cycle, apoptosis, and autophagy-related protein expression were analyzed by western blotting. The efficacy of combination treatment with cisplatin was determined by the Calcusyn software. ART induced HT 1376 and BFTC 909 cell death in a concentration- and time-dependent manner, inducing G ART may be a candidate drug for treating UTUC and bladder UC while increasing the therapeutic effect of cisplatin.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Urothelial carcinoma (UC) may arise from the urothelium of the upper tract and the bladder. Cisplatin-based therapy remains the gold standard for UC treatment. The poor 5-year survival rate of UC patients creates an urgent need to develop new drugs for advanced UC therapy. Artesunate (ART), a traditional Chinese medicine for treating malaria, is a potential anticancer agent, but its antigrowth effects on upper tract and bladder UC have not been investigated.
MATERIALS AND METHODS
METHODS
The antigrowth effect of ART in HT 1376 (bladder UC cells) and BFTC 909 [upper tract urothelial carcinoma (UTUC) cells] was determined by the CCK-8 assay. Flow cytometric analysis was used to evaluate the cell cycle distribution and apoptosis. The cell cycle, apoptosis, and autophagy-related protein expression were analyzed by western blotting. The efficacy of combination treatment with cisplatin was determined by the Calcusyn software.
RESULTS
RESULTS
ART induced HT 1376 and BFTC 909 cell death in a concentration- and time-dependent manner, inducing G
CONCLUSION
CONCLUSIONS
ART may be a candidate drug for treating UTUC and bladder UC while increasing the therapeutic effect of cisplatin.
Identifiants
pubmed: 36854526
pii: 43/3/1175
doi: 10.21873/anticanres.16263
doi:
Substances chimiques
Cisplatin
Q20Q21Q62J
Artesunate
60W3249T9M
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1175-1184Informations de copyright
Copyright © 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.